<?xml version="1.0"?><?xml-stylesheet type="text/xsl" href="../../web/xslt/drug-table.xslt"?><drug name = "erlotinib tab">
<dose><value>100</value>
<value>150</value>
<value>75</value>
</dose><route><value>PO</value>
</route><form><value>tab</value>
</form><drugname><value>erlotinib tab</value>
</drugname><strength><value>100 mg</value>
<value>150 mg</value>
<value>25 mg</value>
</strength><frequency><value>DAILY</value>
</frequency><instruction></instruction><volume></volume><units><value>mg</value>
</units><additionalnotes><value>Dosage adjustments of 50mg due to drug interactions.</value>
<value>A reduced starting dose (75 mg po once daily) has been recommended in patients with (baseline) hepatic dysfunction (transaminases greater than or equal to 3 times ULN AND/OR total bilirubin greater than 3 times ULN).  For patients with normal baseline hepatic function: Treatment should be interrupted or discontinued if total bilirubin is greater than 3 time ULN AND/OR transaminases are greater than 5 times ULN occurs while on treatment.</value>
</additionalnotes><population><value>Erlotinib. Metastatic or Advanced NSCLC.</value>
</population><indicationprn></indicationprn><backgroundinformation><value>http://intraweb01.albertahealthservices.ca/Pharmacy/AHS_FORMULARY/search_details.aspx?id=3387</value>
<value>http://intraweb01.albertahealthservices.ca/Pharmacy/AHS_FORMULARY/search_details.aspx?id=3385</value>
</backgroundinformation><prninformation></prninformation><ahsformularystatus><value>Formulary with Restrictions.</value>
</ahsformularystatus><ahfsname><value>Antineoplastic Agents</value>
</ahfsname><highalert><value>YES</value>
</highalert><maximumprndose></maximumprndose><din><value>02269015</value>
<value>02269023</value>
<value>02269007</value>
</din><type><value>Medication/IV Therapy</value>
</type></drug>